LianBio

About:

LianBio aims to develop and accelerate availability of paradigm-shifting medicines to patients in China.

Website: https://www.lianbio.com/

Top Investors: BlackRock, Pfizer, RA Capital Management, Perceptive Advisors, T. Rowe Price

Description:

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.

Total Funding Amount:

$310M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Shanghai, Shanghai, China

Founded Date:

2019-01-01

Contact Email:

IR(AT)LianBio.com

Founders:

Konstantin Poukalov

Number of Employees:

101-250

Last Funding Date:

2020-10-29

IPO Status:

Public

© 2025 bioDAO.ai